West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļWST
āļāļ·āđāļāļāļĢāļīāļĐāļąāļWest Pharmaceutical Services Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 27, 1923
āļāđāļāļāļąāđāļāđāļĄāļ·āđāļ1923
āļāļĩāļāļĩāđāļMr. Eric Mark Green
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ10600
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJul 27
āļāļĩāđāļāļĒāļđāđ530 Herman O. West Drive
āđāļĄāļ·āļāļEXTON
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNYSE Consolidated
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ19341
āđāļāļĢāļĻāļąāļāļāđ16105942900
āđāļ§āđāļāđāļāļāđhttps://www.westpharma.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļWST
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 27, 1923
āļāđāļāļāļąāđāļāđāļĄāļ·āđāļ1923
Mr. Eric Mark Green
Non-Independent Chairman of the Board, President, Chief Executive Officer
Non-Independent Chairman of the Board, President, Chief Executive Officer
Mr. Douglas A. Michels
Independent Director
Mr. Thomas W. (Tom) Hofmann
Mr. Thomas W. (Tom) Hofmann
Independent Director
Mr. Mark A. Buthman
Independent Director
Ms. Annette F. Favorite
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
Dr. Myla P. Lai-Goldman, M.D.
Dr. Myla P. Lai-Goldman, M.D.
Independent Director
Mr. Paolo Pucci
Independent Director
Mr. Bernard John Birkett
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
Mr. Robert F. (Rob) Friel
Mr. Robert F. (Rob) Friel
Lead Independent Director
Lead Independent Director
Dr. Stephen H. Lockhart, M.D., Ph.D.
Dr. Stephen H. Lockhart, M.D., Ph.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Eric Mark Green
Non-Independent Chairman of the Board, President, Chief Executive Officer
Non-Independent Chairman of the Board, President, Chief Executive Officer
Mr. Douglas A. Michels
Independent Director
Mr. Thomas W. (Tom) Hofmann
Mr. Thomas W. (Tom) Hofmann
Independent Director
Mr. Mark A. Buthman
Independent Director
Ms. Annette F. Favorite
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
Dr. Myla P. Lai-Goldman, M.D.
Dr. Myla P. Lai-Goldman, M.D.
Independent Director
Amplify Weight Loss Drug & Treatment ETF
Motley Fool Mid-Cap Growth ETF
VanEck Morningstar Wide Moat Growth ETF
VanEck Morningstar Wide Moat ETF
VanEck Morningstar ESG Moat ETF
First Trust Indxx Medical Devices ETF
Invesco S&P 500 Equal Weight Health Care ETF
American Century Mid Cap Growth Impact ETF
VanEck Morningstar Wide Moat Value ETF
ProShares S&P 500 Dividend Aristocrats ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Amplify Weight Loss Drug & Treatment ETF
āļŠāļąāļāļŠāđāļ§āļ4.09%
Motley Fool Mid-Cap Growth ETF
āļŠāļąāļāļŠāđāļ§āļ2.63%
VanEck Morningstar Wide Moat Growth ETF
āļŠāļąāļāļŠāđāļ§āļ2.61%
VanEck Morningstar Wide Moat ETF
āļŠāļąāļāļŠāđāļ§āļ2.37%
VanEck Morningstar ESG Moat ETF
āļŠāļąāļāļŠāđāļ§āļ2.14%
First Trust Indxx Medical Devices ETF
āļŠāļąāļāļŠāđāļ§āļ1.93%
Invesco S&P 500 Equal Weight Health Care ETF
āļŠāļąāļāļŠāđāļ§āļ1.62%
American Century Mid Cap Growth Impact ETF
āļŠāļąāļāļŠāđāļ§āļ1.59%
VanEck Morningstar Wide Moat Value ETF
āļŠāļąāļāļŠāđāļ§āļ1.42%
ProShares S&P 500 Dividend Aristocrats ETF
āļŠāļąāļāļŠāđāļ§āļ1.39%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
269.40M
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
WST.NB Interim Cash Dividend of gross USD 0.21 paid on Feb 11, 2025 going ex on Feb 07, 2025
WST.NB Final Cash Dividend of gross USD 0.21 paid on Nov 20, 2024 going ex on Nov 13, 2024
WST.NB Interim Cash Dividend of gross USD 0.2 paid on Aug 07, 2024 going ex on Jul 31, 2024
WST.NB Interim Cash Dividend of gross USD 0.2 paid on May 01, 2024 going ex on Apr 23, 2024
WST.NB Interim Cash Dividend of gross USD 0.2 paid on Feb 07, 2024 going ex on Jan 30, 2024
WST.NB Final Cash Dividend of gross USD 0.2 paid on Nov 15, 2023 going ex on Nov 07, 2023
WST.NB Interim Cash Dividend of gross USD 0.19 paid on Aug 02, 2023 going ex on Jul 25, 2023
WST.NB Interim Cash Dividend of gross USD 0.19 paid on May 03, 2023 going ex on Apr 25, 2023
WST.NB Interim Cash Dividend of gross USD 0.19 paid on Feb 01, 2023 going ex on Jan 24, 2023
WST.NB Final Cash Dividend of gross USD 0.19 paid on Nov 16, 2022 going ex on Nov 08, 2022
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ